These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 8101967

  • 1. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG.
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS.
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD.
    Adv Neurol; 2003 Apr; 91():267-71. PubMed ID: 12442685
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 13. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A, Grondin R, Grégoire L, Calon F, Di Paolo T, Bédard PJ.
    Adv Neurol; 2003 May; 91():51-64. PubMed ID: 12442663
    [No Abstract] [Full Text] [Related]

  • 14. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R, Greenamyre JT.
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [Abstract] [Full Text] [Related]

  • 15. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ, Jenner P.
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [Abstract] [Full Text] [Related]

  • 16. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 17. Down-regulation of dopamine D1 and D2 receptors in the basal ganglia of PTZ kindling model of epilepsy: effects of angiotensin IV.
    Tchekalarova J, Sotiriou E, Angelatou F.
    Brain Res; 2004 Oct 22; 1024(1-2):159-66. PubMed ID: 15451378
    [Abstract] [Full Text] [Related]

  • 18. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J, Dougherty JJ, Nichols RA.
    J Neurochem; 2006 Jul 22; 98(2):481-94. PubMed ID: 16805841
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.